Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523432 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00523432 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 15 participants.
The verdict
NCT00523432, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.
Interventions
- DRUG Topotecan
- DRUG CCI-779 (temsirolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523432
The ClinicalTrials.gov registry entry for NCT00523432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00523432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523432 about?
NCT00523432 is a clinical study titled "A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies". The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.
What is the current status of trial NCT00523432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00523432?
The interventions under investigation include: Topotecan (DRUG), CCI-779 (temsirolimus) (DRUG).
Who is sponsoring clinical trial NCT00523432?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.